en - 安邦生技Anbogen Therapeutics

An innovative company
with deep scientific and clinical expertise
developing best-to-patient
precision oncology medicines

Anbogen Therapeutics (ABT)

ABT is a clinical-stage company
that spun off from the National Health Research Institutes,
the most prestigious medical research institute in Taiwan.
As the leader in advancing Taiwan's biopharma innovation,
we are dedicated to developing the precision cancer therapeuties
that address unmet medical needs and improve lives of cancer patients globally.

Lung cancer is one of the most common cancers with leading cause of death in the world.

Statistics from the WHO indicate

cases of lung cancer in 2020.

making up about 11.4% of all cancer cases,and ranking lung cancer second most common of all cancer types.

In 2020, there were

cases of lung cancer in 2020.

making up about 18% of all cancer cases and ranking lung cancer the number one cause of death from cancer.

Clinical Trials

ABT-101: A tyrosine kinase inhibitor targeting HER2 Exon20 insertion from solid tumor cancer, currently being investigated in Phase1b trial.

ABT-201: A second generation KRAS inhibitor targeting non-small cell lung cancer and other cancer driver genes (KRAS G12C/Y96D double mutation, G12D, G12V, etc.), currently in early development.

ABT-301: A small molecule histone deacetylase inhibitor (HDACi) cancer medication, currently preparing to enter Phase 2 trial.

ABT-101

- Non targeted therapy medication for patients harboring exon 20 insertions (e20i) in HER2 -

ABT-101, is an oral, tyrosine kinase inhibitor (TKI) for non-small cell lung cancer (NSCLC) patients harboring exon 20 insertions (e20i) in HER2, where there’s currently no available treatment for the patients.

ABT-101 demonstrates excellent therapeutic potential and superior safety profile compared to competitors that are under clinical development. It meets challenges of unmet medical needs for cancer drugs targeting exon 20 insertions (e20i) in HER2.

Development Process

Research | IND-enabling | Phase 1 | Phase 2/3

Small molecule inhibitor

ABT-201

-KRAS Targeted Drug-

KRAS inhibitors, like other targeted therapies, is facing the challenge of drug resistance. To meet the unmet medical needs, Anbogen is developing the second-generation KRAS inhibitors to combat resistance mutations as increasing number of clinical studies have shown that patients using Sotorasib® and Adagrasib® have developed novel drug resistance mutations which lead to the drug resistance.

ABT-201 is a second generation KRAS inhibitor target drug developed by ABT's exclusive covalent combination drug design and structural biology design platform, targeting non-small cell lung cancer and other cancer driver genes (KRAS G12C/Y96D double mutation, G12D, G12V, etc.).

Development Process

Research | IND-enabling | Phase 1 | Phase 2/3

Small molecule inhibitor

ABT-301

-Histone Deacetylase Inhibitor-

ABT-301 is a small molecule histone deacetylase inhibitor (HDACi). Due to the fact that cancer cells exhibit higher histone deacetylase activity, the chromosomal compactness are adjusted to block the expression of certain tumor suppressor genes. The application of such inhibitors will facilitate the expression of tumor suppressor genes, which will help alter the growth, arrest, and differentiation of tumor cells, promote apoptosis, ultimately inhibiting the growth of tumor cells and achieving the treatment of cancer.

ABT-301 has demonstrated superior safety in phase 1 study, which opens the possibilities of further clinical development. Data from preclinical studies also show that ABT-301 is highly competitive in treating most solid tumors compared to competing drugs.

Development Process

Research | IND-enabling | Phase 1 | Phase 2/3

Small molecule inhibitor

NEWS

Date	Title
September 2022	AnBogen Therapeutics Receives Approval from U.S. FDA for Phase Ib/II Protocol Amendment for ABT-101 U.S. Food and Drug Administration (FDA) has approved an investigational new drug (IND) protocol amendment for its phase Ib/II trial of ABT-101, an orally administered, irreversible, mutant selective tyrosine kinase inhibitor targeting oncogenic mutations of HER2 Exon20 insertion expressed in non-small cell lung cancer (NSCLC). (Learn More)
March 2022	The ABT101-102 clinical trial was approved by the Ministry of Health and Welfare and will be conducted at multiple medical centers. The ABT101-102 clinical trial is divided into two phases, Phase I and Phase II, to evaluate the safety, tolerability, pharmacokinetics and antitumor efficacy of ABT101 in patients with HER2 Exon20 mutated non-small cell lung cancer (NSCLC) using the BOIN (Bayesian optimal interval design) method. NSCLC patients with HER2 Exon20 mutation, the safety, tolerability, pharmacokinetics and antitumor efficacy of ABT101.
September 2021	Economic Daily News Innovation Industry Special Report- Anbogen Therapeutics. (Learn more)

Award News

2016 Wang Ming-Ning Award

2018 Ministry of Science and Technology Future Tech Awards

2019 International Biomedical Accelerator Partnership Program

2021 National New Innovation Award

Leadership Team

Dr. Tsu-An Hsu

CEO/Founder

Joe Hsueh , MBA

President

Kevin Chih-Yi Hsieh, M.D.

Special Medical Advisor

Chien-Ting Lin, M.D.

Senior Medical Advisor

Angus Tsung-Kai Wu,MBA

VP Business Development

Meng-Chieh Lin, Ph.D.

Director,Pre-clinical Biology

Sue-Ming Chang, Ph.D.

Director,R&D/IP Legal Affairs

Kien-Thiam Tan,Ph.D.

Director,Medical Informatics.

Victoria Ming-Chin Lee,MBA

Clinical Trial Consultant

I-Chu Tsai,PMP

Chemical Manufacturing Control / Clinical Trials

Scientific Advisors

Joe Shih

Co-Founder

Hsing-Pang Hsieh

Co-Founder

Hsing-Jien Kung

Consultant

Kak-Shan Shia

Consultant

Partners

Contact Us